Rigel Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Rigel Pharmaceuticals yıllık ortalama 4.5% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19% annual. Gelirler yılda ortalama 7.3% oranında büyüyor .

Anahtar bilgiler

4.5%

Kazanç büyüme oranı

5.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	7.3%
Özkaynak getirisi	n/a
Net Marj	-10.9%
Sonraki Kazanç Güncellemesi	07 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06

Gelir ve Gider Dağılımı

Rigel Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:RIGL Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	130	-14	108
31 Mar 24	119	-20	106
31 Dec 23	116	-25	106
30 Sep 23	129	-24	110
30 Jun 23	121	-38	112
31 Mar 23	125	-45	113
31 Dec 22	116	-59	112
30 Sep 22	86	-83	105
30 Jun 22	87	-85	102
31 Mar 22	77	-85	97
31 Dec 21	139	-18	92
30 Sep 21	138	-15	89
30 Jun 21	136	-8	84
31 Mar 21	131	-11	80
31 Dec 20	109	-30	77
30 Sep 20	106	-28	73
30 Jun 20	108	-25	74
31 Mar 20	102	-28	73
31 Dec 19	59	-67	75
30 Sep 19	82	-46	78
30 Jun 19	66	-59	78
31 Mar 19	57	-64	76
31 Dec 18	45	-70	70
30 Sep 18	7	-100	63
30 Jun 18	3	-93	53
31 Mar 18	1	-87	44
31 Dec 17	4	-78	38
30 Sep 17	7	-68	30
30 Jun 17	10	-73	27
31 Mar 17	19	-67	24
31 Dec 16	20	-69	21
30 Sep 16	26	-66	18
30 Jun 16	35	-50	18
31 Mar 16	32	-51	18
31 Dec 15	29	-51	18
30 Sep 15	29	-61	20
30 Jun 15	16	-75	20
31 Mar 15	10	-87	22
31 Dec 14	8	-91	23
30 Sep 14	6	-85	20
30 Jun 14	6	-88	20
31 Mar 14	7	-86	20
31 Dec 13	7	-89	20

Kaliteli Kazançlar: RIGL şu anda kârlı değil.

Büyüyen Kar Marjı: RIGL şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RIGL kârlı değildir, ancak son 5 yılda zararlarını yılda 4.5% oranında azaltmıştır.

Büyüme Hızlandırma: RIGL 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: RIGL kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -2.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: RIGL 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Rigel Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Recent updates

Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Price target increased by 34% to US$26.75

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2024

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$0.43 loss

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Focus Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized Covid-19 Patients

Rigel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Now 22% undervalued after recent price drop